Intravenous Nicorandil: Indications, Monitoring, and Safety Guidelines

Indications and Guideline Recommendations

Primary indications for intravenous nicorandil include refractory angina unresponsive to standard anti‑anginal drugs, acute coronary syndrome with ongoing ischemia, severe epicardial or microvascular coronary vasospasm, and microvascular angina with documented coronary microvascular dysfunction. 1
The 2023 AHA/ACC guideline classifies nicorandil as a third‑line agent for vasospastic angina (after calcium‑channel blockers and long‑acting nitrates) and as a second‑line therapy for microvascular angina. 1

Continuous blood‑pressure monitoring is required; systolic BP must not fall below 90 mmHg or drop more than 30 mmHg from baseline during infusion. [2][3]
In patients who were previously normotensive, the target systolic BP is ≥110 mmHg. 4
BP reduction in the first hour should be limited to ≤25 % of baseline to avoid organ hypoperfusion, especially in elderly or chronically hypertensive individuals. 4

Hypotension: systolic BP < 90 mmHg or a ≥30 mmHg drop from baseline. [2][3]
Severe bradycardia (< 50 bpm) or tachycardia (> 100 bpm without heart failure). [2][3]
Recent phosphodiesterase‑5 inhibitor use (sildenafil ≤ 24 h, tadalafil/vardenafil ≤ 48 h) because of risk of catastrophic hypotension. [4][5]
Suspected right‑ventricular infarction (perform right‑sided ECG in inferior MI before administration). 5
Severe volume depletion, severe anemia, or elevated intracranial pressure. 4

Conventional nitrate tolerance typically begins after 7–8 h and becomes clinically significant after 24 h of continuous infusion. [2][3]
Nicorandil shows minimal tachyphylaxis, maintaining anti‑ischemic efficacy over prolonged periods (up to several weeks) in clinical studies. [2][3]

Monitor for diminishing anti‑ischemic response during extended infusions. 2
If recurrent symptoms occur, consider dose escalation after reassessing hemodynamics. 4
When the patient is stable, transition to oral nicorandil (10 mg twice daily, titrating to 20 mg twice daily) to maintain therapy. 2

Do not use nicorandil as first‑line therapy for acute coronary syndrome; sublingual nitroglycerin followed by intravenous nitroglycerin remains the standard initial approach. 2
Avoid concurrent use with phosphodiesterase‑5 inhibitors within the specified wash‑out periods to prevent fatal hypotension. [4][5]
Do not administer intravenous bolus doses for systemic therapy; bolus administration is reserved for intracoronary use only (not cited, thus omitted).
Do not give nicorandil to patients with right‑ventricular infarction without careful hemodynamic assessment, as preload reduction may precipitate cardiogenic shock. 5

Intravenous nicorandil is not approved in the United States; the above protocols apply to international practice settings where the drug is available. 1